Table 4.
Levels of sFas and sFasL in Serum and Expression of Fas/FasL on PBMCs during CL
| Sample | % Cells | Median Fas MFI (IQR) | Median FasL MFI (IQR) | % Apoptosis (IQR) | |
|---|---|---|---|---|---|
| Total PBMC | CL | 12 (3.6) | 5.6 (4.3) | 13* (5.8) | |
| Control | 16 (9.4) | 6.6 (1.8) | 10* (2.0) | ||
| CD19 | CL | 5.1 (2.8) | 7 (3.1) | 5.0* (2.4) | |
| Control | 3.8 (3.0) | 8.8 (6.6) | 7.6* (3.2) | ||
| CD8 | CL | 28 (8.6) | 12 (2.2) | 9.9 (7.1) | |
| Control | 29 (8.8) | 13 (10) | 8.2 (5.2) | ||
| CD4 | CL | 44 (4.0) | 12* (3.7) | 6.0 (5.8) | |
| Control | 49 (5.8) | 22* (11) | 5.8 (0.9) | ||
| CD56 | CL | 19 (6.2) | 11 (3.3) | 6.3 (10) | |
| Control | 22 (11) | 12 (8.8) | 7.6 (2.8) |
Expression of Fas and FasL in total and different subtypes of PBMCs in CL (n = 9 except in apoptosis where n = 7) and controls (n = 7, except in apoptosis where n = 6).
There was a significant reduction of Fas expression on CD4+ cells in CL, although the number of CD4+ cells in patients and controls were similar.
*
P = 0.02.